Drug Trial Radar · NCT00846365
Efficacy and Safety of Azilsartan Medoxomil Plus Chlorthalidone in Participants With Moderate to Severe Hypertension
Last checked: Nov 19, 2026Latest source record: Mar 13, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,085
Actual
Start
Mar 2009
Primary completion
Jun 2010
Study completion Jun 2010
Sponsor
- Lead sponsor
- TakedaTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Feb 18, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the efficacy and safety of azilsartan medoxomil combined with chlorthalidone, once daily (QD), in participants with moderate to severe essential hypertension.
Conditions
- Essential Hypertension
Interventions
Azilsartan medoxomil and chlorthalidoneDrug
Azilsartan medoxomil 20 mg and chlorthalidone 12.5 mg, tablets, orally, and olmesartan medoxomil-hydrochlorothiazide placebo tablets once daily for 8 weeks. If participant does not achieve target blood pressure at Week 4, then the dosage will be increased to azilsartan medoxomil 40 mg and chlorthalidone 25 mg, tablets, orally, once daily for the remaining 4 weeks.
Azilsartan medoxomil and chlorthalidoneDrug
Azilsartan medoxomil 40 mg and chlorthalidone 12.5, mg, tablets, orally, and olmesartan medoxomil-hydrochlorothiazide placebo tablets once daily for 8 weeks. If participant does not achieve target blood pressure at Week 4, then the dosage will be increased to azilsartan medoxomil 80 mg and chlorthalidone 25 mg, tablets, orally, once daily for the remaining 4 weeks.
Olmesartan medoxomil-hydrochlorothiazideDrug
Olmesartan medoxomil 20 mg/hydrochlorothiazide 12.5 mg, tablets, orally, and Azilsartan medoxomil and chlorthalidone placebo-matching tablets, orally, once daily for 8 weeks. If participant does not achieve target blood pressure at Week 4, then the dosage will be increased to olmesartan medoxomil 40 mg/hydrochlorothiazide 25 mg, tablets, orally, once daily for the remaining 4 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline to Week 8 in Trough, Sitting, Clinic Systolic Blood Pressure.Time frame: Baseline and Week 8.
Locations
80 sites in 3 countries. Site status is shown where the registry gives one.
Site not named
Birmingham, Alabama
Site not named
Haleyville, Alabama
Site not named
Hueytown, Alabama
Site not named
Jasper, Alabama
Site not named
Tallassee, Alabama
Site not named
Green Valley, Arizona
Site not named
Phoenix, Arizona
Site not named
Long Beach, California
Site not named
National City, California
Site not named
Roseville, California
Site not named
San Francisco, California
Site not named
San Jose, California
Site not named
Newark, Delaware
Site not named
Clearwater, Florida
Site not named
Jacksonville, Florida
Site not named
Jupiter, Florida
Site not named
Miami, Florida
Site not named
Ocala, Florida
Site not named
Pembroke Pines, Florida
Site not named
Plant City, Florida
Site not named
Tallahassee, Florida
Site not named
Arlington Heights, Illinois
Site not named
Chicago, Illinois
Site not named
Gurnee, Illinois
Site not named
Avon, Indiana
Site not named
Wichita, Kansas
Site not named
Louisville, Kentucky
Site not named
Auburn, Maine
Site not named
Baltimore, Maryland
Site not named
Brockton, Massachusetts
Site not named
Haverhill, Massachusetts
Site not named
North Dartmouth, Massachusetts
Site not named
Bingham Farms, Michigan
Site not named
Stevensville, Michigan
Site not named
Olive Branch, Mississippi
Site not named
Kansas City, Missouri
Site not named
New York, New York
Site not named
Burlington, North Carolina
Site not named
Charlotte, North Carolina
Site not named
Hickory, North Carolina
Showing 40 of 80 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.